BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2025
0mins
Source: Yahoo Finance
Sustained Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis: New three-year data from UCB's Phase 3 trials show that BIMZELX (bimekizumab) provides lasting symptom relief and inflammation control in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), with significant percentages achieving key clinical endpoints like ACR50 and ASAS40.
Safety and Tolerability of BIMZELX: The treatment was generally well-tolerated over the three years, with no new safety signals identified; common adverse events included upper respiratory infections and COVID-19, underscoring the importance of monitoring during treatment.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
